CHRDL1 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine inhibits the hedgehog signaling pathway, which CHRDL1 is known to interact with. By blocking this pathway, Cyclopamine can reduce the functional activity of CHRDL1, which plays a role in modulating bone morphogenetic protein (BMP) signaling. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 acts as a BMP receptor kinase inhibitor. Since CHRDL1 modulates BMP signaling, inhibiting the receptor can decrease CHRDL1's ability to regulate this pathway. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
DMH1 is a selective BMP receptor inhibitor. By inhibiting the receptor, DMH1 can prevent CHRDL1 from exerting its modulatory effects on BMP signaling. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 selectively inhibits the activin receptor-like kinases ALK4, ALK5, and ALK7, which are part of the TGF-β pathway. CHRDL1's modulation of BMP signaling is related to TGF-β signaling, and inhibition of these kinases can reduce CHRDL1's activity. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Dorsomorphin inhibits BMP signaling by targeting the BMP type I receptors ALK2, ALK3, and ALK6. As CHRDL1 interacts with BMP pathways, inhibition of these receptors can reduce the functional effects of CHRDL1. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
Chetomin disrupts the hypoxia-inducible factor (HIF) pathway. Since CHRDL1 is involved in bone development and related to vascularization processes influenced by HIF, Chetomin can indirectly inhibit CHRDL1's function. | ||||||
K02288 | 1431985-92-0 | sc-488981 | 5 mg | $330.00 | ||
K02288 is an ALK2 and ALK3 inhibitor. By blocking these receptors, it can inhibit the BMP signaling pathway, reducing the modulatory effects of CHRDL1 on this pathway. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117 selectively inhibits the BMP type I receptors ALK2 and ALK3, which are involved in BMP signaling. This inhibition can reduce the influence of CHRDL1 on BMP-mediated processes. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A-83-01 inhibits ALK5, ALK4, and ALK7, which are part of the TGF-β superfamily receptors. CHRDL1, through its interaction with BMPs, which are TGF-β superfamily members, may have reduced activity due to the inhibition of these receptors. | ||||||
LDN 193719 | 1062368-49-3 | sc-489383 | 10 mg | $189.00 | ||
LDN 193719 selectively inhibits ALK1 and ALK2, which are receptors involved in BMP signaling. Inhibition of these receptors can lead to a decrease in CHRDL1's modulatory function in BMP pathways. | ||||||